QUECTEL-WIRELESS
26.2.2024 09:01:34 CET | Business Wire | Press release
MWC - Quectel Wireless Solutions, a global IoT solutions provider, has unveiled a new portfolio of Wi-Fi 7 modules that are ideal for PC OEMs looking to support Wi-Fi 7 in their devices’ connectivity technology options. The expanded Quectel Wi-Fi 7 and Bluetooth 5.4 modules range includes the Quectel NCM825, NCM825A, NCM835, NCM865 and NCM865A. All of the new modules offer support for Intel and AMD x86 platforms as well as the Snapdragon® X Elite platform for leading Windows PC experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226076383/en/
Quectel introduces new ultra-low latency Wi-Fi 7 modules for PC OEMs (Photo: Business Wire)
The Quectel NCM825, NCM835 and NCM865 series modules utilize a Qualcomm® FastConnect™ 7800 Mobile Connectivity system from Qualcomm Technologies and support simultaneous operation on the 2.4GHz plus 5GHz and 2.4GHz plus 6 GHz frequency bands thanks to 2 x 2 MIMO with dual band simultaneous (DBS) capability. The NCM865 and NCM865A chipsets feature High Band Simultaneous (HBS) technology, which enhances wireless communication by minimizing interference within the high-frequency spectrum. This advancement contributes to a more efficient use of bandwidth, resulting in decreased latency and an increase in data throughput. The modules also support multi-link operation (MLO), a feature that allows routers to use multiple wireless bands and channels at the same time to connect to a Wi-Fi 7 client. MLO enables the NCM8x5 series to achieve a faster data rate, much lower latency and higher network reliability for users.
“We’re delighted to bring further choice to PC OEMs by adding Wi-Fi 7 and Bluetooth 5.4 modules to our portfolio,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “By harnessing the performance of multi-link operation alongside dual band simultaneous capability we are able to ensure end users can access faster data with ultra-low latency while also continuing to experience outstanding network reliability. This widens the performance envelope for manufacturers and opens up rich experiences and greater flexibility for their customers.”
In addition, the new modules support 4K-QAM and 320MHz bandwidth which enables them to achieve a maximum data rate of 5.8Gbps, allowing the ultra-low latency and real-time response that laptop use cases demand. The modules also integrate and support dual Bluetooth, 2Mbps Bluetooth Low Energy (BLE), LE audio and BLE Long Range.
The Quectel NCM825 series measures 16.0mm x 20.0mm x 1.80mm, while the NCM865 series measures 22.0mm x 30.0mm x 2.25mm. The modules operate in the -10 °C to +65 °C temperature range and variants are certified by regulators across the globe.
Quectel places security at the heart for everything they do. Working closely with Finite State, the leader in managing software supply chain risk for the enterprise, to enhance the security of its modules through rigorous security testing, improved software supply chain visibility, and comprehensive software risk management, ensuring security testing in all phases of the development cycle. In addition to penetration testing of its key modules, Quectel announced the release of Software Bill of Materials (SBOM) and Vulnerability Exploitability Exchange (VEX) documents for its IoT modules. As an industry-first among IoT module manufacturers, these resources will be made available through the Quectel website.
Furthermore, to help customers to facilitate their designs, Quectel offers a variety of high-performance antennas which boost wireless connectivity significantly. IoT developers can bundle Quectel modules along with Quectel’s antennas and pre-certification services, reducing both cost and time-to-market for their IoT devices.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
Qualcomm, Snapdragon and FastConnect are trademarks or registered trademarks of Qualcomm Incorporated.
Qualcomm and Snapdragon branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226076383/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom